Table 2.
Differences in the incidence and severity of side effects among people who received an mRNA or a viral vector vaccine.
| Side Effect | Incidence of Side Effects: Risk Ratio (95% CI) | Incidence of Side Effects: Multivariate Logistic Regression, Coefficient (p-Value) | Severity of Side Effects: Univariate Cumulative Risk Models (p-Value) | Severity of Side Effects: Multivariate Cumulative Risk Models (p-Value) |
|---|---|---|---|---|
| Any side effect | 1.06 (1.01–1.11) | NS | <0.001 | <0.001 |
| Localized reaction | 1.29 (1.19–1.40) | 0.892 (<0.001) | NS | NS |
| Fever | 0.28 (0.24–0.34) | −1.993 (<0.001) | <0.001 | NS |
| Flu-like illness | 0.34 (0.29–0.40) | −1.795 (<0.001) | <0.001 | NS |
| Shortness of breath | 0.43 (0.26–0.70) | −0.853 (0.002) | NS | NS |
| Skin rash | 0.86 (0.40–1.83) | NS | NS | NS |
| Tingling | 0.68 (0.43–1.09) | NS | NS | NS |
| Swelling | 0.29 (0.10–0.80) | −1.326 (0.015) | NS | NS |
| Generalized swelling | 0.29 (0.15–0.56) | −1.423 (<0.001) | NS | NS |
| Anaphylaxis | 0.19 (0.04–0.94) | −1.890 (0.024) | NS | NS |
| Fatigue or tiredness | 0.56 (0.51–0.62) | −1.331 (<0.001) | <0.001 | NS |
| Other | 0.67 (0.52–0.86) | −0.471 (0.004) | NS | NS |
| mRNA vaccines superiority | ||||
| Viral vector vaccines superiority | ||||